Form 4: Emergent BioSolutions Inc. (EBS), Fox Jennifer Lynne, transaction 11/11/2022

Summary

Fox Jennifer Lynne, an Emergent BioSolutions Inc. officer with the title EVP, Ext Aff, GC, Corp Sec, reports on this Form 4 that 416 shares of common stock were withheld on 11/11/2022 at $15. The explanation of responses says the shares were withheld to pay tax liability on shares of restricted stock awarded pursuant to Rule 16b-3(d), which vested on November 11, 2022. Direct ownership afterward was 32,211 shares. The remarks show /s/ Jennifer Lynne Fox, Attorney-in-fact, dated 11/15/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Fox Jennifer Lynne (Last) (First) (Middle) 400 PROFESSIONAL DRIVE SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | Fox Jennifer Lynne | (Last) | (First) | (Middle) | 400 PROFESSIONAL DRIVE | SUITE 400 | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Ext Aff, GC, Corp Sec | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | EVP, Ext Aff, GC, Corp Sec
3. Date of Earliest Transaction
 (Month/Day/Year) 11/11/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 11/11/2022 | F | 416 (1) | D | $ 15 | 32,211 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock of Emergent BioSolutions Inc withheld to pay tax liability on shares of restricted stock awarded pursuant to Rule 16b-3(d), which vested on November 11, 2022.
Remarks:
/s/ Jennifer Lynne Fox, Attorney-in-fact | 11/15/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_EBS_4_filed2022-11-15_0001367644-22-000146.xml

Size

15,101 bytes

SHA-256

f7d1ccce05f42a300129b46146e315c42ff5317172a44724b97a2490fd02701d

Our copy

SEC_EBS_4_filed2022-11-15_0001367644-22-000146.xml

Original

www.sec.gov